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Abstract
Background: Advanced stage head and neck squamous cell carcinoma (HNSCC) is an aggressive cancer with low
survival rates. Loss-of-heterozygosity/allelic imbalance (LOH/AI) analysis has been widely used to identify genomic
alterations in solid tumors and the tumor microenvironment (stroma). We hypothesize that these identified
alterations can point to signaling networks functioning in HNSCC epithelial-tumor and surrounding stroma (tumor
microenvironment).
Results: Under the assumption that genes in proximity to identified LOH/AI regions are correlated with the
tumorigenic phenotype, we mined publicly available biological information to identify pathway segments
(signaling proteins connected to each other in a network) and identify the role of tumor microenvironment in
HNSCC. Across both neoplastic epithelial cells and the surrounding stromal cells, genetic alterations in HNSCC were
successfully identified, and 75 markers were observed to have significantly different LOH/AI frequencies in these
compartments (p < 0.026). We applied a network identification approach to the genes in proximity to these 75
markers in cancer epithelium and stroma in order to identify biological networks that can describe functional
associations amongst these marker-associated genes.
Conclusions: We verified the involvement of T-cell receptor signaling pathways in HNSCC as well as associated
oncogenes such as LCK and PLCB1, and tumor suppressors such as STAT5A, PTPN6, PARK2. We identified expression
levels of genes within significant LOH/AI regions specific to stroma networks that correlate with better outcome in
radiation therapy. By integrating various levels of high-throughput data, we were able to precisely focus on specific
proteins and genes that are germane to HNSCC.
Background
HNSCC is the sixth most common cancer and remains a
major cause of cancer morbidity and mortality worldwide
[1]. More than 85% of head and neck squamous cell car-
cinomas (HNSCC) are related to tobacco use, while
others may have a relationship to viral etiologies such as
human papillomavirus (HPV) infection/colonization.
Nevertheless, advanced stage HNSCC remains an aggres-
sive cancer with low survival rates. Molecular studies
suggest that HNSCC results from cumulative epigenetic
and genetic alterations [2-4]. Various genomic regions
and/or genes have been correlated with survival in
HNSCC or classified as early detection/aggressiveness
markers [2]. Albeit incomplete, such baseline knowledge
of HNSCC genetics builds a foundation for exploration
of functional associations between these structural altera-
tions and tumorigenesis. Identifying such networks
through a more systematic examination of HNSCC is a
challenge and the focus of this study.
Recent genome-scanning technologies uncovered an
unexpectedly large amount of structural variation (SV) in
the human genome [2,5-9]. Structural variations com-
prise a large set of alterations including deletions, dupli-
cations, large-scale copy-number variants, inversions and
translocations in the genome [10]. On the extreme, can-
cer genomes are known to attain frequent alterations in
their gross chromosomal structure by amplification, dele-
tion, translocation and/or inversion of chromosomal
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genes, produce multiple copies of genes thereby increas-
ing gene activity or, in rare situations, result in the fusion
of two genes. Alterations in tandem may be critical to
cancer onset and progression.
Loss-of-heterozygosity/allelic imbalance (LOH/AI)
scanning has been widely used to identify genetic altera-
tions in tumor samples. The absence or an imbalanced
signal of a DNA marker in the tumor sample would sug-
gest LOH/AI in these cancerous cells [12]. Numerous
studies reporting localized and/or genome-wide LOH/AI
analyses have discovered specific loci with consistently
high frequencies of LOH/AI in HNSCC. These observa-
tions have provided key clues for identification of tumor
suppressor genes in this malignancy [2,13]. Moreover, it
is now common practice to utilize laser capture micro-
dissection (LCM) and LOH/AI analysis of tumor com-
partments, namely, neoplastic epithelial cells and the
surrounding cancer-associated (previously presumed to
be non-cancerous) stromal cells (part of the tumor
microenvironment) [14-21]. For example, LOH/AI analy-
sis of DNA from the neoplastic epithelial cells of invasive
breast carcinomas and surrounding stroma revealed that
stromal somatic mutations of TP53 in stromal cells, but
not epithelial neoplasia, correlated with regional nodal
metastases [22]. In the absence of stromal TP53 muta-
tion, LOH/AI at 5 specific loci in the stromal cells also
correlated with regional nodal metastases [22]. Subse-
quently, only with extensive empiric molecular and cell
biology studies did a mechanism for this genetic observa-
tion emerge [23]. In general, however, extended func-
tional associations of genes within these regions with
their cellular signaling mechanisms have yet to be made.
It is hoped that the approach described here will mini-
mize the time and effort put forward for pinpointing
functional mechanisms from tumor-associated bicom-
partmental somatic genomic observations without pro-
longed repeated empiric work on multiple candidate
pathways.
In this study, therefore, we have applied an integrated
network discovery framework [24-26] to identify distinct
signaling pathway networks (SPN) of the two compart-
ments of HNSCC. Genes of interest are surveyed and sig-
naling networks identifying genes affected by these
variations are visualized. We also investigated bicompart-
mental genomic alterations and their associated SPN’si n
the context of radiation therapy and human papilloma
virus (HPV) status, both germane factors in HNSCC
treatment response. Ultimately, our systems biology
approach of pathway identification should provide
invaluable knowledge in understanding the inter-com-
partmental and inter-network-based events in HNSCC
tumorigenesis and importantly, guide empiric molecular
and cellular biology experiments in a targeted manner.
Results
To identify signaling pathway networks for HNSCC
stroma and epithelium compartments, we devised a com-
putational workflow in which we integrated our own
empirically-derived LOH/AI analysis of genomic DNA
from epithelial and stromal compartments of 122
HNSCC specimens [16] with publicly available HNSCC-
derived genome-wide genomica n df u n c t i o n a l - g e n o m i c
datasets and high-throughput proteomics and cellular
data (Figure 1). In this approach, we processed large-
scale genome-wide scans of HNSCC tumors to generate
a list of candidate genes. This list is then used to search
for likely HNSCC-relevant signaling pathways in the
pathway analysis framework (based on [24-26]).
LOH/AI gene identification
Genotyping of 366 microsatellite markers of both epithe-
lium and stroma samples from the 122 patients’ HNSCC
tumors (Table 1) revealed 75 marker locations as signifi-
cant for frequent genomic alterations. This set of 75 mar-
kers was examined in this study. LOH/AI regions that
have significantly higher frequencies of LOH/AI compared
with other markers along the same chromosome are
defined as hot spots, as previously operationally defined via
a model-based approach [16,22]. Regions that have signifi-
cantly lower frequencies of LOH/AI compared with other
markers along the same chromosome are termed cold
spots (See Additional File 1, Table S1 and Table S2 for a
complete list of markers). The hot and cold spots identi-
fied [in either compartment] are approximately equal in
number (37 hot spots vs. 34 cold spots [See Table 2]).
However, the number of hot/cold spots (hot spots + cold
spots) identified only in stroma is about three-fold com-
pared to those identified in the epithelium. In addition to
these 71 markers to be brought forward for integration
with other platforms, we also included four more markers
that we previously found to correlate with tumor size (one
from stroma) and regional nodal status (two from stroma
and one from epithelium) in HNSCC in this set [16].
For this set of 75 markers, we extended marker locations
250 kb in both directions of a marker to identify genes
within proximity. The parameter (250 kb) was chosen for
computational flexibility. This extension returned 273
genes that lay within proximity of these marker locations
(See Additional File 1, Table S3). The number of genes
included in the region increases linearly as the flanking
regions are extended (See Additional File 2, Supp. Text).
A larger set of genes diminishes the effectiveness of the
methodology since the number of unrelated genes
increases. For instance, if genes within the same loci of
identified markers are used (> 250 kb, varying based on
loci size), the mapping would return ~2200 genes for
these 75 markers. Thus, we decided against this all-
encompassing approach so that we could establish an
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tary text and Additional File 3, Figure S4).
Genes are filtered by establishing networks
The pathway identification framework utilizes various
datasets including mRNA gene expression profiles, tis-
sue-specific genotyping data, protein-protein interactions,
protein subcellular localization data, and functional
annotations of genes (Gene Ontology [27]), to connect
genes within proximity of the 75 significant LOH/AI
marker locations in a signaling network (see Methods for
a brief description). For calculating associations, genes
not linked to HNSCC through this integration step were
dropped from further consideration. The remaining gene
list from the 75 marker regions was divided into two sub-
sets according to their subcellular compartment (See
Additional File 1, Table S4 and Table S5 for a complete
list of epithelium and stroma markers and genes used).
First, a global protein-protein interaction network was
built by integrating these data sources. Next, gene lists
from these marker locations were utilized to search for
networks that are specific to the two compartments. In
this framework, the interaction network was queried for
signaling proteins connected to each other on a linear
path (pathway segments). Using these signaling chains
acquired in the search process (p-value < 0.01, please see
supplementary methods for details), signaling pathway
networks from the stroma and epithelium were generated
Figure 1 Workflow for high-throughput data integration to help understand the molecular basis of cancer.A ni n t e g r a t i v e- o m i c s
signaling network identification process workflow that begins with processing tissue specific data (instrument outputs). Microarray data is
normalized to make comparisons of expression levels and transformed to select genes for further analysis. LOH/AI signals are analyzed to identify
regions (and hence regional genes) for both tumor and normal tissue (or noncancerous cells). Next, genes observed within proximity of these
markers are merged with their corresponding microarray probes to create expression profiles. In this analysis step, expression profiles are used to
calculate Pearson’s coexpression correlations among gene pairs. These results are fed into the Pathway Analysis Framework. Integrating gene-
gene coexpression values, annotations from Gene Ontology, known signaling pathwas, protein sequence information, protein-protein interaction
networks, and protein subcellular colocalization data, pathways are predicted and filtered. Significant pathway subnetworks are merged to form
signaling networks connecting genes of interest. The networks and structural variations identified are put together to create a descriptive
functional network, creating a molecular basis for the cancer studied. This type of workflow, which we utilized, can be applied to using
integrative systems biology approaches to study cancer and other pathologies.
Bebek et al. Journal of Clinical Bioinformatics 2011, 1:21
http://www.jclinbioinformatics.com/content/1/1/21
Page 3 of 15(Figure 2). These networks depict significant signaling
events that occur in the two compartments. Signaling
events such as T-cell signaling, EGFR-PTK2B signaling,
and interactions between various tumor suppressors and
oncoproteins were identified which shape the set of fil-
tered genes (see Discussion for extended analysis).
Signaling networks highlight functional associations of
tumor related genes
Signaling events in the cell play a critical role in the
execution of key biological functions. To further investi-
gate the role of the filtered genes within LOH/AI
regions of interest, we searched for signaling pathway
networks, which were generated using mRNA expres-
sion levels, known key signaling pathways, protein-pro-
tein interactions, and characteristics of these proteins.
The signaling pathway search greatly decreased the
number of genes associated with each marker (down
~ 5 0f r o m2 7 3 ) .I nt h i sw a y ,a ne x t e n d e dl i s to fg e n e s
was reduced to a short list of genes that are functionally
correlated with one another in the HNSCC context.
We then compared our short list of genes with the
oncogenes and tumor suppressor genes that have been
previously identified to be associated with HNSCC and
other cancers in earlier studies (listed in Table 2). Earlier
studies may have identified genes of interest by observing
their structural loss or reduction in function. In the pre-
sent work, our network search workflow (Figure 1) has
been successfully verified by identifying genes that were
previously associated with HNSCC. For further verifica-
tion, we found that our methodology accurately identified
g e n e st h a tw e r ep r e v i o u s l yi d e n t i f i e da st u m o rs u p p r e s -
sors, proto-oncogenes and metastasis-related genes in
earlier studies (see Additional File 1, Table S6, Table S7
and Table S8). In addition, the generated networks
included known head and neck cancer biomarkers. Com-
mon fragile site genes (DAG1 and PARK2) and various
genes that have elevated expression patterns in cancers
are also connected in these networks.
Structural variations are involved in initiation and
progression of HNSCC
Listed in Table S9 are genes that likely have structural
variations, i.e., hot spot marker genes that harbor gene
gain or loss in HNSCC. Transcriptional profiles of
HNSCC using both stroma and epithelium network-asso-
ciated genes were hierarchically clustered to show that
we have acquired networks depicting the connections of
HNSCC aberration sites. In other words, we wished to
see if the likely alteration of genes in these networks is
also altering functionality of these genes in cancers. We
also observed that most network-associated genes are
consistently turned off, and only a small number of genes
have increased expression, such as RHOA, CDC2,a n d
CREM in stroma (Figure 3).
In summary, networks signifying medium- to large-
scale structural variations are predicted through integra-
tion of genome-wide LOH/AI analysis, tumor-derived
Table 1 Patient Characteristics (N = 122)*























Low G1 or 2 83 (80.6
High G3 20 (19.4)
* Data were not available for all patients.
Using laser capture microdissection, epithelium and stromal tissue
compartments of squamous cell cancer lesions of head and neck from 122
samples were acquired.
Table 2 Hot spot-, cold spot- and clinicopathological
feature-associated microsatellite markers identified in
HNSCC tissue compartments
Compartment LOH/AI Markers
Epithelium and stroma Hot spots 5
Cold spots 6
Epithelium only Hot spots 10
Cold Spots 7
CPF 1




Using laser capture microdissection, epithelium and stromal tissue
compartments of squamous cell cancer lesions of head neck from 122
samples were acquired. 366 microsatellite markers were used to identify
significantly higher/lower frequency of LOH/AI at a marker or markers
compared with other markers along the same chromosome. The table shows
the number of cold spot, hot spot or clinicopathological features (CPF)
identified in epithelium only, stroma only, and both in epithelium and stroma.
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mic, pathway and annotation data.
Verifying networks identified via cluster analysis of mRNA
expression data
To strengthen our claim that the generated networks are
highly significant in describing the disease, in this case
HNSCC, we also analyzed randomly picked genes from
the protein-protein interaction database, the primary data-
base of the computational framework. We acquired micro-
array expression levels from the same mRNA dataset for
these genes and generated an unsupervised clustering for
these genes for comparison. These clusters show increased
disarray (See Additional File 3, Figure S2) when compared
to the expression patterns of the genes placed in the net-
work through the computational framework.
Since we have observed that in a highly significant net-
work, most genes have altered expression, we have also
generated similar clustering with biased selections. We
compiled lists of genes associated with HNSCC from
PubMeth (Reviewed methylation database of cancer
genes [28], Additional File 1, Table S9) and from litera-
ture search (Additional File 1, Table S10). Since these
lists consist of genes that are positively correlated with
HNSCC, we first generated unsupervised clustering of
these listed genes utilizing the HNSCC mRNA expres-
sional data in a similar fashion. We also merged each of
these two lists with our network genes and re-clustered
these genes. We observe that PubMeth genes can classify
HPV+ and HPV- HNSCC and normal tissue mRNA
expression profiles, while the literature scan gene list
cannot deliver similar classification (Figure 4). However,
the latter were still able to classify normal tissue versus
HNSCC as a whole. The combined lists show that our
findings are consistent with prior observations, thus sup-
porting our network-based conclusions (Figure 5).
Figure 2 The signaling pathway networks. Networks are generated for stroma only and epithelium only with p < 0.01. The proteins
(represented by nodes) are placed in their intra-cellular localization, with the plasma membrane represented at top and the nucleus at the
bottom. The nodes are colored blue if they are within 250 kb of an identified cold spot and red if they are within 250 kb of an identified hot
spot. Pink nodes represent the intermediary proteins identified through the computational framework. The interaction colors represent the
Pearson’s correlation coefficient (r) of the two neighboring proteins’ mRNA levels. If the edge is colored red, the two proteins have a positive
mRNA expression correlation, whereas green represents the opposite. The solid edges show known interactions, while the dashed edges are
interactions predicted via homology/family information [24]. The predicted interactions are bolded if they are verified with independent studies
through a literature search.
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We have further analyzed the above identified HNSCC
epithelium- and stroma-associated network genes (Fig-
ure 2) using Global Test [29]. Global Test is a
statistical test that can be used to identify association
between the expression profile of groups of genes and
a given outcome. In this case, we utilized this statistic
to extract causal gene clusters that correlate with
Figure 3 Stroma network clustered via mRNA expression levels. mRNA expression levels of (A) Epithelium and (B) Stroma network proteins
are clustered using hierarchical clustering. Horizontal clustering depicts genes and vertical clustering groups tumors through expression levels.
The labels below represent HNSCC tumors with HPV status (+ or -) and normal tissue included in the mRNA expression microarray study [47].
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may be viewed as an important form of genotoxic
stress. For these purposes, we have included seven
sets of genes, significant microsatellite marker-
associated genes (Additional File 1, Table S4 and
Table S5), the genes identified in stroma and epithe-
lium networks (Additional File 1, Table S6 and Table
S7), the intersection of the two networks, and only the
Figure 4 HNSCC-associated genes cluster via mRNA expression levels. A: PubMeth (Reviewed methylation database of cancer genes, [28])
genes associated with HNSCC B: Literature surveyed HNSCC associated genes are clustered using the mRNA expression profiles to show
classification power of earlier HNSCC studies compared to genes identified through the network framework.
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networks. When genotoxic stress outcome (sensitive/
resistant) was measured in head and neck tumor cell
lines [30] (GSE9714) and NCI Anti-Cancer Drug
Screen (NCI60) cell lines [31] (GSE7505), only the
stroma-associated genes (Table 3 and Additional File
1, Table S5) were statistically significant using the glo-
bal test statistics.
Figure 5 (A) Epithelium and (B) Stroma network and methylated genes clustered via mRNA expression levels. PubMeth (Reviewed
methylation database of cancer genes, [28]) genes associated with HNSCC are marked with ‘x’, and network genes are marked with ‘+’. The
heatmaps show corroboration of our findings with earlier studies, hence strengthening our discovered networks [2,13,52].
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In this study, we sought to identify signaling pathway net-
works in HNSCC-derived carcinoma and their associated
stroma by genotyping DNA from each compartment with
microsatellite markers and integrating independent pub-
licly available HNSCC-relevant somatic microarray-based
mRNA expression and other datasets [32], resulting in a
first description of integrative -omics-derived genes to sig-
naling pathway networks in the neoplastic epithelial carci-
noma cells and the surrounding tumor-associated stromal
fibroblasts. We followed a computational workflow that
integrates extensive amounts of high-throughput data,
namely protein-protein interactions, gene ontology anno-
tations, protein colocalization data, and known signaling
pathways to form signaling networks that can lead to a
better understanding of HNSCC (Figure 1). In addition, it
is hoped that this type of approach would also result in
specific pathways that can be targeted for empiric study
linking genomic variation and pathogenesis without taking
a candidate approach in functional analysis.
Genetic alterations such as copy number aberrations or
LOH/AI have been shown to be associated with HNSCC
initiation and progression [2]. In LOH/AI testing, the
microsatellite markers are informative in a location-specific
manner, however, these markers are an average of 9 cM
apart. Hence, we extended the coverage to 250 kb flanking
each side of the 75 significant (71 hot + cold spot markers
+ 4 markers associated with tumor size/nodal metastases)
marker locations to generate a list of genes in close proxi-
mity. By choosing a shorter segment of the genomic region
(s) near a significant marker (500 kb/marker instead of
the marker’s whole locus, in this case, 9 × 2 cM), we were
able to narrow our search space and increase efficiency and
minimizing false positives. We believe that our approach
has identified significant genomic regions with viable func-
tional associations. In this study, we have utilized
microarray data that were generated from tumor samples
that were at least 80% tumor cellularity [32]. An 80%
tumor-cellularity does not mean 20% are stroma. Because
we are looking at tumor-associated stroma, the 80%
tumor-cellularity should also contain its tumor-associated
stromal cells, but the precise make-up is unknown. The
lack of publicly available subcompartment-specific gene
expression profiles certainly poses its own challenges.
However, since the pathway analysis is seeded from the
genomic alterations of the subcompartments, the microar-
ray data should still carry general patterns of expression
profiles from head and neck tissue. Hence, the resulting
pathways so identified should represent reasonably accu-
rate stroma- and epithelium-specific signaling pathway net-
works. The generated networks contain a significant
number of stroma- and epithelium-specific genes identified
through the genotyping experiments. The networks reflect
this classification via utilization of an integrative -omics
approach. This reduces any false signals that might be
introduced via any platform that is utilized.
Signaling pathways of HNSCC
In this study, identifying large numbers of frequent LOH/
AI in stroma suggests that genetic alterations in this
compartment of the tumor precede the genetic alteration
in the surrounding cells, which might be consistent with
the well-known field-effect theory of cancerization
[33,34]. We report networks based on these significant
markers, which also highlight hot spot marker genes that
mostly cluster in the stromal network. In recent studies,
the interaction of epithelium and stroma of breast carci-
noma was investigated [14,35,36]. Similar to our observa-
tion in HNSCC, the location of the LOH/AI regions in
the epithelial cells of breast cancer are concentrated in a
smaller region, specifically, a smaller number of markers
with much higher LOH/AI frequencies; whereas in the
Table 3 Proteins in the signaling networks associated with structural hot- and cold-spots generated for stroma and
epithelium of HNSCC
Category Stroma Epithelium
Tumor Suppressor Gene ACVR1B, DOK2, PARK2, PTPN6, STAT5A DOK2, PTPN6, STAT5A
Proto-oncogene CRK, EGFR, LCK, SRC EGFR, LCK, PARK2, SRC
HNC Biomarker SFN CAV3
Oncogenic when overexpressed RHOA
Increased expression in Cancers CDC2, CREM, HOXB4, NTSR2, PVR, PVRL1 ADRBK1, CCR4, HOXB4
Inactive in Cancers DAB1
Serine/threonine protein kinase CAMK2A, GSK3A PRKCG
Role in Metastasis GSC, PLCG1 PLCB1, PLCG1
HNSCC association not identified
yet
ADAM15, BSN, CBLC, CNTN4, EMX1, GRIN2B, HOXB1, KRT82, SKAP1,
TLE6
DSCAM, EMX1, GRIN2B, HOXB1, SKAP1,
TLE6
The categories are determined by consensus literature terms. Genes whose products are studied as or utilized as drug targets are emboldened. Overall,3 1
proteins in stroma and 21 for epithelium are identified through the signaling pathway search framework (Refer to Additional File 1 Table S6 and Table S7 for
more details and references).
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over a larger number of loci. Using these observations, a
model of carcinogenesis was developed, at least for breast
cancers: transformation initiates in the epithelial cells
(higher LOH/AI frequencies) while stromal genomic
alterations may dictate biology and in term affect the
epithelial component [14]. This genomic observation has
been mechanistically validated [23].
We have observed a larger number of genetic alterations
in the tumor stroma than in the epithelium. Additionally,
not all changes in epithelium are observed in stroma.
However, these added changes could play a different and
parallel role in HNSCC carcinogenesis. This observation
parallels the findings of independent studies showing
somatic mutations and/or LOH/AI in the stroma of breast
cancer [14,37] colon cancer [37], bladder cancer [38], and
ovarian cancer [39]. It is plausible that the large number of
markers involved in the stroma of HNSCC and bladder
cancer could represent a field effect after exposure to
shared carcinogens. Just as in other cancers such as those
of the breast, the diversity of markers in the stroma may
explain biological diversity [14]. The changes in the stroma
resulting from alterations in the signaling pathways may
then cross-talk with the cancer epithelium and induce
genomic instability, as has been shown by Lisanti’s group
for breast cancers [23].
Similarities and differences between stroma and
epithelium networks
The identified signaling pathway networks point out differ-
ences in signaling in stroma and in epithelium (Figure 2).
In investigating the expression correlations among proteins
to identify the pattern of up/down regulation in tumors ver-
sus their corresponding normal tissues, PARK2 (Parkinson
disease [autosomal recessive,j u v e n i l e ]2 ,p a r k i n ) ,ag e n e
lying in a hotspot, was found to be common in both com-
partments’ networks. PARK2 is within the fragile site
FRA6E on chromosome 6, a region shown to be unstable
and prone to breakage and rearrangements. DAG1 from
this region was observed as inactivated in multiple cancers
[40]. We observe that both of these genes in HNSCC are
affected (Figure 2) with likely loss of expression.
EGFR-PTK2B signaling modulates ubiquitin (Ub)/pro-
teasome pathway-mediated intracellular trafficking.
PYK2B activation is also critical for the activation of
SRC downstream of EGFR, which we do not observe in
HNSCC. In this study, we observe that EGFR transactiva-
tion prevented the phosphorylation of the nonreceptor tyr-
osine kinases PYK2B and SRC, locating these kinases
downstream of the transactivated EGFR as noted.
Although as highlighted in the signaling networks, SKAP1
(SRC kinase associated phosphoprotein 1) is identified as a
cold spot, the lack of signaling starting through EGFR pre-
vents SRC activation. SRC is expressed at low levels in
most cell types and, in the absence of appropriate extracel-
lular stimuli, maintained in an inactive conformation.
We associated genes that are activated or have gain-of-
function in other cancers with those found in HNSCC, e.
g., HOXB4, PVR, RHOA, ADRBK1 and CCR4. Pathways
that are common to multiple cancers can be identified by
incorporating these types of oncogenes from multiple stu-
dies (Additional File 1, Table S6 and Table S7). Moreover,
genes like CCR4 and GSK3A highlighted in this study are
already candidate targets for therapy in other cancers [41].
Human breast, ovarian, renal, lung and colon tumor speci-
mens have been analyzed for somatic RHOA mutations
previously. No intragenic mutations in RHOA were found,
nor a correlation between RHOA mRNA expression and
the presence or absence of 3p21 deletions. This suggests
likely duplication of RHOA in HNSCC as well (also veri-
fied by the increased mRNA expression levels shown in
Figure 2) [42].
Regulatory T cells are important in modulating antitu-
mor immune response. In both compartments, we see
T-cell related signaling proteins, such as proto-oncogene
LCK (T cell-specific protein-tyrosine kinase), tumor sup-
pressor PTPN6 (Tyrosine-protein phosphatase), and
SKAP1 (Src kinase-associated phosphoprotein 1). In cells,
SKAP1 has a critical role in inside-out signaling (regula-
tory signaling that originate within the cell cytoplasm and
are then transmitted to the external ligand-binding
domain of a receptor) by coupling T-cell antigen receptor
stimulation to the activation of integrins. In both compart-
ments, SKAP1 interacts with LCK, which is most com-
monly found in T cells (Figure 2). In an earlier study [43],
STAT5B was shown to contribute to LCK-induced cell
proliferation and resistance to apoptosis. Similarly
STAT5A,aSTAT5B isoform, might be carrying out a simi-
lar activity in HNSCC. Hence, increased constitutive acti-
vation of STAT5 was detected in transformed compared
with normal squamous cells. It is known that blockade of
TGF-alpha or EGFR,e n d e dSTAT5 activation [44]. How-
ever, observing down regulation of EGFR in this cancer
(Figure 2 and Figure 3), we conclude that the control on
proliferation is lost.
HNSCC biology is consistent in both HPV+ and HPV-
patients
In this study, we did not observe differences in biological
networks of HNSCC with and without human papilloma-
virus (HPV) in the context of the stroma. HPV infection
is a strong risk factor for HNSCC [45] regardless of other
factors such as tobacco or alcohol use. However, it
should be noted that the HPV “effect” is germane only in
certain oropharyngeal sites of HNSCC. Furthermore,
depending on the manner and quantity of subtyping
HPV, in fact, the jury is still out regarding the role of
HPV in HNSCC. Unsupervised hierarchal clustering of
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a n de p i t h e l i u ms h o w e dt h a tt he expression patterns of
HPV+ and HPV- patients are similar (Figure 3) in these
networks. In essence, we hypothesize that these networks
represent the biology in both tissue types, since they are
built upon the genomic alterations and integrated with
tissue specific message signals. Therefore, these heat
maps, as opposed to subclustering into two patient
groups (+ and -), reveal that only patient and normal
sample differences are observed. Interestingly, when
methylated genes are clustered via the same microarray
data used in our network identification, the HPV+ and
HPV - patients clearly separate from each other (Figure
4). To rule out that this might be due to tumor site dif-
ferences, since HPV+ cases are observed with highest
prevalence in oropharynx and base of tongue [46], we
have repeated this clustering with a subset of patients
that are site matched (11 pairs matched by site and
stage), and observed a similar result (Figure S3).
The difference in methylated genes between HPV+
and HPV- patients is mostly due to changes in cellular
machinery caused by either HPV’s integration into the
genome or the latter’s inflammation-related effects on
methylation. For instance p16 (CDKN2A)i sk n o w nt o
be overexpressed in HPV+ HNSCC patients [13].
Although these differences were explained by HPV
modifying the cellular expression machinery to create
different expression profiles [47], our networks show
that the essential genes in tumorigenesis are similar in
both patient groups. In other words, HPV integration
affects genes with similar downstream consequences as
other mutational events observed in HPV- tumors.
Hence, HNSCC-relevant pathways derived from LOH/
AI regions of HNSCC as shown in our results (Figure 2,
and Figure 3) has not been differentiated with HPV
initiated HNSCC. Indeed, our current data suggest that
whether it is HPV-associated or not, what is important
are the final common pathways.
HNSCC is a result of cumulative genetic and epige-
netic alterations [2]. In this study, we have only consid-
ered genetic markers of HNSCC and mRNA levels in
the tissue to measure these changes. The computational
data mining approach can be easily adapted to include
any other high throughput experimentation, such as
methylation profiles, single nucleotide polymorphisms
etc. In future studies, using this successful workflow as a
basis, we will extend our knowledgebase to fine map
HNSCC signaling pathway networks.
Stroma may mediate better response to radiation therapy
We have also investigated therapeutic predictive value of
the networks identified. Utilizing human head and neck
cancer tumor cell lines [30], the identified gene lists
were subjected to a statistical test [29] to monitor their
correlation with response to radiation therapy (see
Methods). Expression of genes that are found within
250 kb on either side of each hot and cold spot LOH/AI
markers in the stroma were statistically significant
(Table 4; p-value = 0.029)w h e nc o r r e l a t e dw i t h
response to radiation therapy (151 genes were tested).
This is significant since although these therapies are
aimed to eliminate solid tumors, the genomic landscape
of the tumor stroma is more significant in acquiring
response to genotoxic stress, most likely harboring a
response for both compartments. One of the significant
results based on our networks is that hot or cold spot
gene expression levels in stroma of tumor may lead to a
significant benefit to cancer patients undergoing radia-
tion therapy, which is commonly used in HNSCC treat-
ment. Further investigation is needed to identify the
pathways associated with these genes harboring
response to radiation. We have also looked at NCI60
cell lines to see whether the general expression profiles
of genes can be replicated in a wide range of tumor cell
types. Although HNSCC cell lines do not exist in the
NCI60 cell line array, this broad range of cells would
give a general idea of how variations in gene expression
among these cells would correlate to radiation response.
Interestingly, expression of the hot/cold spot genes in
the stroma network (14 genes) were statistically signifi-
cant (Additional File 1, Table S11; p-value = 0.026)
when correlated with response to radiation therapy.
Conclusions
The proposed framework establishes valuable founda-
tions towards building tumor-specific signaling pathway
networks, which in return will provide a more thorough
understanding of the pathobiology of HNSCC. The fra-
mework not only reduces the search space but also
e n a b l e su st of o c u so ns p e c i f i cp r o t e i n sa n dg e n e st h a t
are active in HNSCC, including novel proteins related to
molecular mechanisms involved in HNSCC. Pathways
and networks are built up efficiently, utilizing widely
available high-throughput data and providing powerful
discovery tools for research. Our present work also
demonstrates that this approach and framework can be
applied to the tumor microenvironment whose role in
tumorigenesis, invasion, progression and response in
therapy will only gain in prominence [22,23,48].
Methods
Hot and cold spots of LOH/AI in HNSCC
In our study, we analyzed HNSCC samples that were
previously collected and genotyped in an earlier study
[16]. The two compartments of the neoplastic tissue
(epithelium and stroma) in 122 samples (Table 1) were
isolated using LCM as previously described in [16].
LOH/AI markers used in this study have coverage of 7
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marker distance. In total, 366 microsatellite markers
were analyzed in both epithelium and stroma samples
from the 122 patients (Overall 244 samples, 122 epithe-
lium and 122 stroma samples of the 122 patients). In
this earlier study, all significant regions were named hot
spots, attributing to their importance, regardless of their
LOH/AI frequency.
In this study, hot and cold spots of regional LOH/AI
are defined and identified. The LOH/AI regions that
have significantly higher frequency of LOH/AI (p-value
< 0.05) at a marker or markers compared with other
markers along the same chromosome are named hot
spots. In contrast if LOH/AI regions have significantly
lower frequency of LOH/AI (p-value < 0.05) at a marker
or markers compared with other markers along the
same chromosome, we named these regions cold spots
(See Table 2 for a summary, Additional File 1, Table S1
for epithelium hot/cold spots, and Additional File 1,
Table S2 for stroma hot/cold spots). Since hot spot
regions have significantly higher frequencies of LOH/AI,
we expected to observe variation in these regions,
whereas cold spots are regions that were less likely to
carry variation. Among the 75 genomic locations of
interest, 34 of them are cold spots, and 37 are hot spots.
We also included four more markers that correlate to
tumor size and nodal status that is not characterized as
hot or cold spot in HNSCC (three of the four observed
in stroma, and one in epithelium) [16].
Tissue specific mRNA microarray data acquisition
Based on the assumption that genes affected by carcino-
genesis should reflect their altered state on their respec-
tive mRNA expression levels, we acquired HNSCC
somatic expression array data. Genes within close proxi-
mity of significant markers of LOH/AI can be associated
with the available expression array data to further reveal
relationships that can lead to clues about the role of
these genes in biological pathways. Hence, publicly avail-
able microarray expression data for HNSCC is acquired
f r o mt h eG e n eE x p r e s s i o nO m n i b u s[ 3 2 ] .T h ea r r a y
source is screened by the platform used, tissue (for con-
trols) and tumors analyzed. The probe sets in this study
are processed using the robust multiarray averaging
(RMA). In this publicly available data set human gene
expression levels were measured using Affymetrix U133
Plus 2.0 arrays. This array is a comprehensive genome-
wide expression analysis chip that analyzes the expres-
sion level of over 47,000 transcripts and variants. We
have merged all of the expression profiles and calculated
the Pearson’s Correlation Coefficient of all the genes
over all the samples.
Identifying signaling pathway networks of HNSCC
Network analysis frameworks are commonly used for
computational analysis of high-throughput molecular
interaction data and are useful in determining the conser-
vation and divergence of functional organization in biolo-
gical systems. Current widely used approaches are
generally limited to specific target patterns, such as con-
served sub-networks and motifs utilizing shortest path
algorithms, nearest neighbor queries or topological prop-
erties based on limited abstractions from well annotated
pathway databases such as KEGG. On the other hand, the
computational framework utilized in this study (Figure 1)
facilitates identification of components and features of the
cellular network that characterize similarities and differ-
ences between cancerous and normal cells from a func-
tional perspective. Details of this framework are given in
the supplementary text.
Identifying genes within vicinity of LOH/AI markers
First, possible LOH/AI regions of HNSCC are identified
using a similar approach presented in [14]. Although
carcinogenesis pathway of HNSCC does not directly
represent functional relationships of cancer related
Table 4 Microarray profiles of radiation response in the NCI60 cell lines
Gene Group Genes Tested Statistic Q Expected Q sd of Q p-value
Epithelium Network (EN) 21 20 0.12173 0.68791 0.70898 0.82857
Stroma Network (SN) 32 27 8.9873 6.0567 3.4807 0.2
Intersection of EN & SN 14 13 0.14672 1.0085 1.0742 0.85714
Hot/Cold spots in SN 14 11 7.2921 5.187 6.0014 0.28571
Hot/Cold spots in EN 9 8 0.050848 0.096741 0.05459 0.77143
Genes within 250 K of Epithelium Markers 79 61 18.863 8.8517 9.2183 0.17143
Genes within 250 K of Stroma Markers 235 151 56.296 10.686 10.746 0.02857
The network genes identified for stroma and epithelium of HNSCC as well as genes within 250 kb of stroma- and epithelium-associated markers are tested via
Global Test [29], a statistical test scoring for association of the expression profile of groups of genes for outcome (e.g. response to radiation treatment: resistant/
sensitive). Overall seven sets of genes were tested, and only hot- and cold-spot-associated genes within the stroma network (red/blue colored nodes in Figure 2)
was shown to be significant, i.e., expression profiles of stroma-associated genes at hot-/cold-spots are associated with increased sensitivity to radiation. mRNA
expression profiles are acquired from GEO (GSE9714), a study reporting gene expression profiles of radiosensitive and radioresistant human head and neck tumor
cell lines [30].
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ing pathways via a more systematic and integrated
manner.
The LOH/AI regions identified from the signaling path-
way will be associated with possible genes. Although each
marker can correspond to more than one gene, by associat-
ing the genes with available high-throughput data that is
related to cancer, genes can be eliminated. Here our
assumption is that, if these LOH/AI regions are correlated
with each other in terms of carcinogenesis, the effect should
be observed in expression levels as well as interaction pat-
terns of these genes after translation. Hence, if the genes
within close proximity of these markers are associated with
available high-throughput data, we should observe these
relationships and eventually form hypotheses over func-
tional relationships of these genes in terms of pathways.
Previous studies [49-51] have used a similar approach,
where they measured gene expression through mRNA
levels to identify tumor suppressor genes in HNSCC. Iden-
tifying these hot spot genes will allow us to form a hypoth-
esis of the functional relationships among these genes.
Identifying gene expression correlation with outcome via
Global Test
Global Test is a statistical test, giving a score for associa-
tion of the expression profile of one or more groups of
genes to a given outcome [29]. The test is based on the
Cox proportional hazards model and is calculated using
martingale residuals. This procedure allows us to test
hypotheses about the influence of these groups of genes
on survival directly; in our case response to genotoxic
stress. A study reporting large-scale gene expression
changes in response to genotoxic stress is utilized. The
data is downloaded from GEO (accession GSE7505) [31].
In this dataset, radiation response was measured in NCI60
cell lines using NHGRI Homo sapiens 6 K array. Out of
the 63 array samples, 15 cell lines were labeled as sensi-
tive/resistant to genotoxic stress. Using these 15 samples
and the seven set of genes (hot and cold spot genes (Addi-
tional File 1, Table S4 and Table S5), stroma and epithe-
lium networks genes (Figure 2, Additional File 1, Table S6
and Table S7) and their intersection, and only the hot/
cold spot genes that are identified in these two networks)
the global test is run and p-values are acquired (Table 4).
P-value calculation method was done using permutations
over the whole microarray experiment downloaded. The
number of permutations was limited to number of genes
on each array used.
Unspervised hierarchial clustering of gene expression
profiles
The gene expression profile of each sample is first nor-
malized by transforming values so that the mean is 0
and the standard deviation is 1. The clustering is
performed by calculating Pearson’s correlation coeffi-
cients between mRNA expression profiles over all sam-
ples and based on these distances building dendograms
with hierarachical clustering method as it is implemen-
ted in Matlab (Matworks, Natick, MA). The heatmaps
are generated based on the final clustering.
Additional material
Additional file 1: Supplementary Tables S1-S11 is provided in this
file.
Additional file 2: Additional description of the methods followed in
the study is provided in this file.
Additional file 3: Supplementary figures supporting the results is
provided.
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